A biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases, endocrine disorders and oncology within niche markets that have unmet medical needs.


Updates from The Motley Fool

Latest updates on Insmed from Fool.com.
This Week in Biotech

Mixed clinical data, a potential buyout, an untimely clinical hold, and a potential breakthrough ...

Why Insmed Shares Soared

An analyst powwow sends Insmed higher, but are shares now overvalued?

The Best of 2012: Insmed

Now we begin our look at the top gaining 25 stocks in the healthcare space with #25, up 134% this...

Top Stocks at Half-Price

Investors still think highly of these companies, despite their fire-sale prices.



Stock Performance

View Interactive INSM Charts
Sponsored by

Key Data Points

Primary metrics and data points about Insmed.
Current Price: $17.35
Prev Close: $17.24
Open: $17.26
Bid: $12.16
Ask: $32.52
Day's Range: $17.01 - $17.54
52wk Range: $9.02 - $19.35
Volume: 308,754
Avg Vol 304,880
Market Cap: $1B
P/E (ttm): -5.92
EPS (ttm): ($2.91)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Insmed.
CAPS Rating 2 out of 5
 
78 Outperform
12 Underperform
CAPS All Stars
 
13 Outperform
7 Underperform

How do you think Insmed will perform against the market?



You pick for Insmed is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Will Lewis, CEO

100% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Insmed.

A biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases, endocrine disorders and oncology within niche markets that have unmet medical needs.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers